Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DNA beats Street consensus, Idec to miss

Genentech (DNA) posted first quarter 2000 EPS of $0.28, beating the consensus Street estimate by $0.02. However, while sales of Rituxan rituximab, an anti- CD20 antibody to treat non-Hodgkin's lymphoma licensed from Idec

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers